Results 11 to 20 of about 2,752 (194)

Safety of indacaterol in the treatment of patients with COPD [PDF]

International Journal of COPD, 2011
James F Donohue1, Dave Singh2, Oliver Kornmann3, David Lawrence4, Cheryl Lassen4, Benjamin Kramer5 1University of North Carolina, Chapel Hill, NC, USA; 2University of Manchester, Medicines Evaluation Unit, Manchester, UK; 3IKF Pneumologie GmbH and Co KG,
Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B   +5 more
doaj   +7 more sources

Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD [PDF]

New England Journal of Medicine, 2016
Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear.We
Jadwiga, A., Wedzicha, M. D., Donald, Banerji, Kenneth R, M. D. ., Chapman, M. D., Jørgen Vestbo, M. D., Dmsc, D. M. S.c., Nicolas Roche, M. D., R. Timothy Ayers, M. S.c., Chau, Thach, Phd, P.h. D., Robert, Fogel, M. D. Francesco Patalano, M. D., Claus F., Vogelmeier, M. D., for the FLAME, Investigators, FOSCHINO BARBARO, MARIA PIA   +16 more
core   +12 more sources

Indacaterol: a comprehensive review

International Journal of Chronic Obstructive Pulmonary Disease, 2013
At present there is no cure for chronic obstructive pulmonary disease (COPD). However, some nonpharmacologic treatments, such as rehabilitation and lung volume reduction surgery, as well as pharmacologic intervention, can relieve some of the patient's symptoms and improve quality of life, while also reducing the rate of exacerbations and ...
Rossi,Andrea, Polese,Guido
openaire   +6 more sources

Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD [PDF]

Respiratory Medicine, 2016
Our previous studies suggested that the site of bronchodilation on CT might differ between inhaled β2 agonists and inhaled anticholinergics in COPD.To assess and compare the bronchodilation effects of inhaled indacaterol and glycopyrronium/indacaterol by airway generation in large airways using CT.CT scans at full inspiration and pulmonary function ...
Kaoruko Shimizu, Ruriko Seto, Hironi Makita, Masaru Suzuki, Satoshi Konno, Yoichi M. Ito, Rie Kanda, Emiko Ogawa, Yasutaka Nakano, Masaharu Nishimura   +9 more
openaire   +5 more sources

Indacaterol/Glycopyrronium Combination for COPD [PDF]

Pulmonary Therapy, 2017
In all current guidelines and recommendations of the management of COPD, inhaled bronchodilators are the pillar of therapy at each stage of the disease. Dual bronchodilation with long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) is always more effective than the LAMA or LABA alone in terms of the improvement in trough FEV1, and ...
Cazzola, Mario, Ora, Josuel, Puxeddu, Ermanno, Rogliani, Paola   +3 more
openaire   +4 more sources

Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease

International Journal of COPD, 2015
Naoki Inui,1,2 Sayomi Matsushima,1 Shinpei Kato,1 Hideki Yasui,1 Masato Kohno,1 Tomoyuki Fujisawa,1 Noriyuki Enomoto,1 Yutaro Nakamura,1 Mikio Toyoshima,3 Takafumi Suda1 1Second Division, Department of Internal Medicine, 2Department of Clinical ...
Inui N, Matsushima S, Kato S, Yasui H, Kono M, Fujisawa T, Enomoto N, Nakamura Y, Toyoshima M, Suda T   +9 more
doaj   +1 more source

Bronchodilator efficacy and safety of indacaterol 150 µg once daily in patients with COPD: an analysis of pooled data

International Journal of COPD, 2011
Eugene R Bleecker1, Thomas Siler2, Roger Owen3, Benjamin Kramer41Center for Genomics and Personalized Medicine Research and Translational Medicine Institute, Wake Forest University Health Sciences, Winston-Salem, NC, USA; 2Midwest Chest Consultants ...
Bleecker ER, Siler T, Owen R, Kramer B
doaj   +1 more source

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study [PDF]

Respiratory Research, 2017
Dual bronchodilator therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD). There are limited data on effects of a combination of two long-acting bronchodilators on lung function including body plethysmography.This multicentre, randomised, double-blind, single-dose, cross-over, placebo-controlled study ...
Salomon, J., Stolz, D., Domenighetti, G., Frey, J.G., Turk, A.J., Azzola, A., Sigrist, T., Fitting, J.W., Schmidt, U., Geiser, T., Wild, C., Kostikas, K., Clemens, A., Brutsche, M.   +13 more
openaire   +7 more sources

Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences

International Journal of COPD, 2014
Takeshi Ohno,1 Shota Wada,1 Souichirou Hanada,1 Hirochiyo Sawaguchi,1 Masato Muraki,1 Yuji Tohda21Department of Respiratory Medicine and Allergology, Nara Hospital, Kinki University Faculty of Medicine, Ikoma, Japan; 2Department of Respiratory Medicine ...
Ohno T, Wada S, Hanada S, Sawaguchi H, Muraki M, Tohda Y   +5 more
doaj   +1 more source

Translational study searching for synergy between glycopyrronium and indacaterol

European Respiratory Journal, 2014
Background QVA149 is a combination of indacaterol and glycopyrronium (Dahl, R. et al. Respir Med 2013;107:1558-67). Aim To investigate the interaction of indacaterol and glycopyrroniumin in inducing acute bronchodilation.
CAZZOLA, MARIO, Calzetta, L, SEGRETI, ANDREA, Facciolo, F, ROGLIANI, PAOLA, Matera, M.   +5 more
openaire   +6 more sources